Introduction
Immunoassay is a common method used to measure a wide variety of measurands for a wide range of applications. Because immunoassays typically utilize two or more antibodies, the measurands most amenable to immunoassay have sufficient molecule size to allow binding of one or more antibodies and for the production of antibodies which have high specificity to the measurand. As such, large molecules, such as proteins and glycans, are most often measured by immunoassay. The high measurement specificity of immunoassay, their robustness, speed, and low-cost, as well as the simplicity of instrumentation used in immunoassay all contribute to the widespread use in food analysis, forensics, and medical diagnostics. Due to the widespread use of immunoassay, NMIs (and/or their designated institutes) are often tasked to provide metrological support for routine use of immunoassay and may now, or in the future, employ immunoassay in their own measurement and calibration services. The CCQM study P58.1 assessed the equivalence of immunoassay measurements between participating NMIs.
The aim of P58.1 was to demonstrate the equivalence of immunoassay measurements to determine the mass concentration of the clinically-relevant protein human cardiac troponin I (cTnI) present at low concentration relative to the protein concentration of the sample matrix. The measurement equivalence will be assessed using traceability to a common certified reference material. To quantify cTnI, participants will use a homogeneous sandwich-based immunoassay with an enzymatic amplification step. The antibody format consists of a single capture and single detection antibody (referred to as 1 + 1), both were supplied to study participants. The CCQM study P58.1 assessed the utility of a candidate immunoassay reference procedure to quantify a protein antigen based on the detection of two epitopes within the antigen. For this approach to succeed, a complete understanding and assessment of the uncertainty associated with the use of an immunoassay is required to assign mass values to a secondary certified reference material (CRM) from the concentration of a primary CRM. The P58.1 study determined the uncertainty associated with the use of the candidate reference immunoassay to assign values of the concentration of human cardiac troponin I (cTnI) in an aqueous protein solution. In the previous P58 study, ELISA measurement results were compared between laboratories which all used common ELISA reagents (including 96-well plates), samples, a standard for the production of calibrants, and a detailed ELISA protocol, which were supplied by a single laboratory. The P58.1 study only utilized common samples, a standard of the production of calibrants, and a set of monoclonal antibodies (mAbs). Because much of the experimental procedure for the P58 study was essentially standardized across participating labs, the study primarily highlighted betweenlaboratory differences in plate sampling designs and in plate reader response. As the participants in the P58.1 study had to produce most of their own analytical reagents and develop their own measurement procedure, the study provides a better evaluation of the equivalence of ELISA measurements between the participating laboratories.
Description of the Measurand
The immunoassay used in P58.1 targets human cardiac troponin I through the use of two mouse monoclonal antibodies. The epitope of the monoclonal antibody (mAb 560) used for antigen capture is the region between residue 83 and residue 93 of human cTnI. For detection of the bound protein and signal generation, another monoclonal antibody was used (HyTest mAb 19C7), its epitope being the region between residue 41 and residue 49.
Participants
All participants (Table 1 ) have agreed to have their respective results identified throughout this report. 
Preparation of Samples
The samples for P58.1 were prepared at NIST through gravimetric dilution of NIST SRM 2921 (Human Cardiac Troponin Complex). The dilution buffer was 20 mmol/L Tris (Sigma-Aldrich), 150 mmol/L sodium chloride (Fluka), 1 mmol/L calcium chloride (Sigma-Aldrich), pH 7.4 containing 7.5 g/L bovine serum albumin (BSA) (Sigma-Aldrich). The final level of cTnI in the three study samples were in the range 0.5 μg/L to 10 μg/L. Approximately 200 aliquots of each of the three samples were prepared in 500 μL polypropylene screw-cap vials (Sarstedt), each with a sample fill volume of approximately 300 μL. After preparation and aliquoting, all samples were stored at ≤ -70 °C. The immunoassay capture anti-human cTnI mAb clone 560 and detection antihuman cTnI mAb clone 19C7 were purchased from HyTest Ltd., Finland. The choice of these monoclonal antibodies was based on the recommended guideline and research finding (1, 2).
Homogeneity testing of Samples
The homogeneity analysis of unknown sample 2 was performed on 8 vials from each sample batch; 4 vials were chosen randomly from early in the fill order (i.e., vial numbers 1 through 50) and 4 vials were chosen randomly from late in the fill (vial numbers 150 through 200). From each of the 8 samples, three aliquots were analyzed using the candidate reference measurement procedure (RMP), described in Appendix2, on a single plate. Through comparison of the ELISA fluorescence intensity readouts from all 8 samples shown in Figure 1 , no evidence of sample inhomogeneity of unknown sample 2 was observed. As all three samples are similar in nearly every aspect, it is assumed that the homogeneity observed for sample 2 also reflects the homogeneity of sample 1 and sample 3. Both pre-study test runs by us and actual study runs performed by participants validated the assumption.
Stability testing
Stability testing of unknown sample 1 was performed with four sets of two vials of the samples stored at approximately 22 °C, 5 °C, and -20 °C, (with remaining sample aliquots stored at -80 °C) for approximately 3 days, 14 days, 28 days, and 42 days. Using an isochronous study design at the end of the 42 day study period, all aliquots were analyzed by the same ELISA method described below on a single plate. Through comparison of the ELISA response from all 26 vials as shown in Figure 2 , there was a statistically significant decrease in the measured cTnI responses of samples stored at -20 °C relative to those stored at 5 °C (p < 0.0001). T-test showed no difference between cTnI responses of samples stored at 5 °C and at 22 °C (p = 0.242). Significant difference in cTnI responses was also observed between the control samples stored at ≤ -70 °C and samples stored at approximately -20 °C (p < 0.0001). Therefore, unknown samples were shipped to participants with dry ice and specified to be stored at ≤ -70 °C prior to the measurement. As all three samples are similar in nearly every aspect, it is assumed that the stability observed for sample 1 also reflects the stability of sample 2 and sample 3. Both pre-study test runs by NPL and actual study runs performed by participants validated the assumption.
Distribution of samples and report instructions
The P58.1 study description that was send to participants is in Appendix 1. Each participating institution was sent three vials each of Samples 1 through 3 and was requested to store these samples at ≤ -70 °C and thawed completely before subsamples were taken for measurement. Participants were requested to analyse three separate sub-samples from each of the three P58.1 samples provided. The analysis of all three samples was repeated on a separate day, again with the analysis of each sample with triplicate aliquots. Participants additionally received three vials of the human cardiac troponin I standard (NIST SRM 2921) and were asked to store at ≤ -70 ºC until used to prepare calibration solutions. Participants also received stock solutions of the capture and detection monoclonal antibodies to be used in the 1+1 ELISA. Approximately 19 μL of a 5.3 mg/mL solution of capture mAb clone 560 and approximately 95 μL of a 3.6 mg/mL solution of detection mAb clone 19C7 were sent to participants. Participants were requested to store both mAb stock solutions at approximately 4 °C until used. A detailed ELISA protocol (developed at NPL, see Appendix 2) was supplied to all participants as an example of a methodology that could be used in this study. Participants were requested to report:
•
The measured mass concentration of the cTnI in Samples 1 through 3 expressed in μg/L.
• A full uncertainty budget for the mass concentration of cTnI in Samples 1 through 3.
• An outline of the methodology, a full measurement equation and a breakdown of the uncertainty estimation submitted.
Participant method details
Although participants were provided with an example protocol, they were free to use any method, reagents (excluding antibodies and primary calibrant), or modify the protocol to fit in-house procedures. Twelve out of 15 participants returned data sets within the designated study period. NIMT supplied data after the deadline for data submission. Two participants (BAM and IRMM) performed the assay and measured on two instruments (Table 2 ). The mean response from these two instrument data sets was used in all subsequent data analysis unless indicated. CENAM provided data run on two independent assays: RT-PCR and a commercial clinical analyser. The clinical analyser used by CENAM did not employ the monoclonal antibody pair supplied to the participants, a requirement of this study. Therefore, for statistical analysis, 13 unique data sets were used in the P58.1 study, excluding the data from NIMT and one of the sets submitted by CENAM. Where indicated, all participants used a diluent containing 7.5 g/L BSA except NPL who used a diluent containing 75 g/L BSA to prepare the cTnI calibration samples. The use of fluorescent standards to compare/normalize plates and understand the uncertainty associated with the instrument (plate reader) was not performed by all participants. Table 2 . Experimental factors used by the P58.1 study participants. Table 2 highlights which participants used this approach and the fluorescent standard employed. Table 3 details the reported measured cTnI concentrations for samples 1, 2 and 3, the given uncertainty estimate and coverage factor used. Participants were asked to develop an uncertainty equation for the use of immunoassay technique to quantitate cTnI using SRM2921. The uncertainty equations where provided by participants have been listed in Appendix 4, with the majority of the participants identifying two sources of uncertainty that they considered to be significant, that associated with repeated measurement and the uncertainty associated with the certified concentration of cTnI in the common standard used for calibration (i.e., SRM 2921).
Participant Data and Uncertainty Estimates
Many of the uncertainty components estimated by participants were influenced by the cTnI sample tested. Table 4, Table 5 and Table 6 express the uncertainty components as a percentage of the total uncertainty. Based on participants prior knowledge and measurements performed during the study to assess the contribution of certain assay steps the magnitude of uncertainty components varies considerably from participant to participant. Uncertainty associated with repeated measurement and that associated with the certified concentration of the calibration material SRM 2921 are common as significant contributor to the overall uncertainty across the majority of participants. confidence interval of the median. Robust statistics were used to analyze the P58.1 study data to reduce the impact of inconsistent results. Because the results from NIMT were submitted after the study deadline and after other study participant's data had been made available, the NIMT results were not used in any data analysis. The commercial clinical assay results submitted by CENAM (CENAM_2) did not use the anti-cTnI clones 560/19C7 in a similar format as requested in the P58.1 study protocol. Therefore, the measurand defined in the P58.1 study as epitopes specific to clones 560 and 19C7 was not specifically measured by the commercial clinical assay. As such, the CENAM_2 results were not included in the analysis of the P58.1 study data. However, the NIMT and CENAM_2 results are included in Figure 3 through Figure 5 to facilitate comparisons.
Analysis of Results

Coherent Statistical Analysis
In the P58. (4) showed that discrepancies between immunoassay concentration estimates due to statistical analyses can be substantial. Eight participants provided raw data (i.e. intensity measurements and calibrant concentrations) for each measured immunoassay plate. We reanalyze each of these data sets by the same statistical method (4). This method consists of a non-linear regression with heteroscedastic Gaussian errors for the calibration and subsequent prediction of the unknown concentration -both tasks are solved applying Bayesian inference. Previously, this approach was shown to be applicable and to give reliable estimates and uncertainties. Bayesian analysis requires prior distributions. These priors are newly developed for the current study, because the priors used previously for analysis of the P58 study data (4), relied on additional measurements of control samples which are unavailable in P58.1. On the other hand, an assumption of no prior information on any of the calibration parameters (requiring uninformative prior distributions) leads to identifiability issues for at least three immunoassay data sets in this study. Instead, information (i.e. expertise), gained during the precursor P58 study, can be used to derive prior distributions for the current study. Because the precursor study P58 covered a wide range of experimental settings (different international participants, different laboratory equipment, personnel and procedures, etc.), we can assume that the calibration curves estimated for P58 (and their uncertainties) cover the plausible range of future calibration curves if
• the intensity measurements and calibrant concentrations are suitably scaled, and if • the measurements can be assumed to follow the same statistical model (the 4-parametric logistic function and Gaussian errors whose variance is linear in the concentrations). Approximating (or smoothing) the posterior distribution of each calibration parameter from all P58-participants with a parametric distribution from a heavytailed family (the t-distribution in particular) may thus represent the knowledge which was available prior to performing the current study and is displayed in Figure of Appendix 7. The robustness of estimates and uncertainties with respect to the employed prior distributions were tested. For those data sets of the current study where application of uninformative prior distributions on all calibration parameters is possible, the estimates and uncertainties are almost identical to the ones displayed below. For the remaining data sets, the employed prior distributions solve identifiability issues and thus enable an analysis. 
Estimates and Uncertainties from the Coherent Statistical Analysis
Application of the Bayesian approach leads to cTnI concentration estimates for each immunoassay plate. Subsequent linear pooling (5) of these two or three plate estimates (i.e. adding their posterior distributions), gives the P58.1 cTnI concentration estimates for Samples 1 through 3 displayed in Figure 6 through Figure 8 , respectively. None of the cTnI concentration estimates attained by each participant's approach contradict the ones from the Bayesian approach (i.e. the intervals overlap). More remarkable, however, is that all the uncertainties evaluated by the Bayesian approach are larger for sample 1 and most are larger for samples 2 and 3, compared to each participant's approach. In other words, especially at lower concentrations, part of the immunoassay variability is not well-explained by simpler statistical methods (such as the linear fit suggested in the data analysis section of Appendix 2).
Comparing the raw plate cTnI concentration estimates derived by the common Bayesian approach (displayed in Figure A4 through Nevertheless, a few of the plate estimates differ significantly between the methods (plate 1 of IRMM_1 and IRMM_2, plate 2 [and plate 1 for sample 2] of NPL). Additionally, substantial discrepancies between plate estimates of the same participant remain (for INMETRO, IRMM, NMIJ, NPL and UME for the Bayesian approach) -especially for large concentrations. That is, some sources of immunoassay variability are (currently) not captured by an analysis of a single immunoassay plate. While two or three independent repeated measurements 1 display this variability in the current study, this was not the case in the previous P58 study (possibly due to the more restrictive P58 protocol). 
Overall Results and Discussion
The combined data for all methods are presented in Table 7 , and for ELISA only protocols in Table 8 , i.e. excluding the clinical analyser submitted by CENAM. Because the results from NIM-T were submitted after the study deadline and after other study participant's data had been made available, the NIMT results were not used in any data analysis. The commercial clinical assay results submitted by CENAM (CENAM_2) did not use the anti-cTnI clones 560/19C7 in a similar format as requested in the P58.1 study protocol. Therefore, the measurand defined in the P58.1 study as epitopes to clones 560 and 19C7 was not specifically measured by the commercial clinical assay. As such, the CENAM_2 results were not included in the analysis of the P58.1 study data (Table 7 and Table 8 ).
In addition to the data obtained from the P58.1 study, Table 7 and Table 8 also list the "gravimetric" [cTnI] concentrations of all three samples. The "gravimetric" concentration is an estimate of the concentration of each samples based on the gravimetric dilution and the certified concentration of SRM 2921, from which the samples were prepared. As there is the possibility of cTnI losses during the more than 1000-fold dilution process used to prepare the study samples (due to, for example, cTnI adsorption onto pipette tips and other surfaces), the "gravimetric" concentration of the samples might not reflect the actual concentrations. The "gravimetric" concentrations should be considered to be the highest possible cTnI concentration of each sample, the expected concentration if there was no loss of cTnI during sample preparation. Participants employed different approaches to test either the 2, or 3 batches of unknown cTnI standards provided, for example using common calibration samples between different plates (batches of cTnI samples). A plot comparing the uncertainty from each of the participant plates, highlighting intraplate error is shown in Appendix 3, Figure  A1 , Figure A2 , and Figure A3 , respectively for Samples 1, 2 and 3. Comparison of uncertainty either within-plate, or plateto-plate (including fresh preparation of the calibration samples) did not highlight an obvious trend. Where significant plateto-plate variation occurred (compared to the intra-plate variation), this could indicate that either repeatability of the immunoassay technique or the preparation of the calibration response was resulting in significant uncertainty. The bias plot in Figure 9 highlights any non-linearity associated with the quantitation of the cTnI samples using the immunoassay method. Data has been normalised relative to the median response from all participants (average response from the IRMM and BAM data sets used in the calculation of the mean). Assay non-linearity in determination of the unknowns will be highlighted by a wide distribution in bias values obtained for each of the cTnI samples. A plot of the cTnI concentration as estimated using gravimetric dilution, and the median response from all methods (Figure 10 ), generates a good correlation with an adjusted r 2 of 0.994. The correlation observed suggests linearity of the ELISA approach for determination of the cTnI concentrations represented by the samples analysed within the P58.1 study.
Similar meta-analyses can be carried on the basis of the results from the coherent statistical analysis. On the level of laboratory concentration estimates the Bayesian cTnI concentration estimates appear largely consistent with each other. One possibility to investigate this for each sample in detail is an analysis based on a linear fixed effects model (6). Such an analysis is robust to inconsistent measurements, and under the assumption of at least 4 consistent measurements, it suggests the reference concentrations listed in Table 9 (and also depicted in Figure 6 through Figure 8 as the solid and dashed horizontal lines in gray) . Note that only eight laboratories (BAM (set 1), INMETRO, IRMM (set 1), KRISS, NMIJ, NPL, PTB, and UME) contributed to this reference value, because one of each of the double estimates for BAM and IRMM were excluded and five laboratories did not contribute raw data for the Bayesian analysis. Also in Table 9 are the median (and associated uncertainties) cTnI concentrations calculated from the values submitted by these participating labs. The fact that the estimated reference concentrations (calculated from the coherent statistical analysis of participant's raw data) in Table 9 have smaller uncertainties than the median of the values submitted by study participants is caused by the difference in methods to estimate this reference (and not necessarily by the difference in concentration estimates for each participant). Additionally, the analysis gives evidence that one participant has measured sample 2 with bias, and two participants have measured sample 3 with bias (not shown).
Comparison of P58 and P58.1 Study Results
The data obtained from the P58.1 can be compared to the previous P58 study that used ELISA for the quantitation of human interferon α2β (3). For the P58 study all the reagents were provided to the participant The P58 study design contrasts to P58.1, where only the analyte, reference sample and antibodies were provided. In the P58 study, the betweenlaboratory variability in the measured concentration of the single unknown sample used in the study was approximately 6 %. As indicated in Table  8 , the between-laboratory variability for all three samples used in the P58.1 study was approximately 27 %. The higher level of between-laboratory variability in the P58.1 study can potentially be explained by a number of factors. Probably the most important factor is that the P58.1 study required participants to produce most of their ELISA reagents (most importantly, labelled and immobilized antibodies) while all reagents (including well-plates) were supplied to participants in the P58 study. Another difference between the P58 and P58.1 studies that may have contributed to higher betweenlaboratory variability in the P58.1 study is the concentration of the unknown sample. In P58, the concentration of the human interferon α2β in the study sample was approximately 1000-fold higher than any of the three cTnI samples used in the P58.1 study. One would anticipate higher between-laboratory variability for the measurement of very low concentration samples.
P58.1 Scope of Applicability
The P58.1 study supports a measurement claim for the determination by immunoassay of the mass concentration of a protein present in an aqueous protein solution for which the matrix protein concentration is significantly larger than the measurand concentration and the matrix protein composition is simple (one or a few matrix proteins). 
Introduction
The CCQM study P58.1 will assess the utility of using an immunoassay format to quantify a protein antigen based on the detection of two epitopes within the antigen. For this approach to succeed, a complete understanding and assessment of the uncertainty associated with the use of an immunoassay is required to assign mass values to a secondary certified reference material (CRM) from the concentration of a primary CRM. The P58.1 study will determine the uncertainty associated with the use of the candidate reference immunoassay to assign values of the concentration of human cardiac troponin I (cTnI) in an aqueous protein solution. Ultimately the P58 studies may lead to a key comparison based on the use of immunoassay for the value assignment of the mass concentration of a protein analyte in a complex-matrix CRM such as human serum. The aim of P58.1 is to demonstrate the comparability of an immunoassay measurement to determine the mass concentration of a clinically-relevant protein (cardiac troponin I) present at low concentration relative to the protein concentration of the sample matrix. The measurement comparability will be assessed using traceability to a common certified reference material.
To quantify cTnI, participants will use a homogeneous sandwich-based immunoassay with enzymatic amplification step. The antibody format consists of a single capture and single detection antibody (referred to as 1 + 1). The detection antibody is coupled to an enzyme such as alkaline phosphatase, the relative concentration of which can be determined optically using a suitable fluorescent substrate. Participants will need access to a fluorescent plate reader, capable of measuring an enzymatic substrate, such as 4-MUP.
Description of the Measurand
The immunoassay used in P58.1 target human cardiac troponin I through the use of two mouse monoclonal antibodies. The epitope of the monoclonal antibody (MAb 560) used for antigen capture is the amino acids between residue 83 and residue 93 of human cTnI. For detection in the immunoassay, the epitope of the monoclonal antibody used (HyTest MAb 19C7) is the amino acids between residue 41 and residue 49.
Preparation of Samples
The final level of cTnI in the three study samples is expected to be in the range 0.5 μg/L to 25 μg/L. All three samples were prepared by gravimetric dilution of NIST SRM 2921 ("Human Cardiac Troponin Complex") with 7.5 g/L bovine serum albumin in 150 mmol/L NaCl, 5 mmol/L CaCl 2 , 20 mmol/L Tris, pH 7.4. Approximately 200 aliquots of each of the three samples were prepared in 500 μL polypropylene screw-cap vials, each with a sample fill volume of approximately 300 μL. After preparation and aliquotting, all samples were stored at -80 °C.
Homogeneity testing of Samples
The homogeneity analysis of Sample 2 was performed on 8 vials from each sample batch; 4 vials were chosen randomly from early in the fill order (i.e., vial numbers 1 through 50) and 4 vials were chosen randomly from late in the fill (vial numbers 150 through 200). From each of the 8 samples, three aliquots were analyzed by the ELISA method developed by NPL (see Appendix 2) on a single plate. Through comparison of the ELISA response from all 8 samples, no evidence of sample inhomogeneity of Sample 2 was observed. As all three samples are similar in nearly every aspect, it is assumed that the homogeneity observed for Sample 2 also reflect the homogeneity of Sample 1 and Sample 3.
Stability testing
Stability testing of Sample 1 was performed with four sets of two vials of the samples stored at 22 °C, 5 °C, and -20 °C, (with remaining sample aliquots stored at -80 °C) for approximately 3 day, 16 days, 28 days, and 45 days. Using an isochronous study design at the end of the 45 day study period, all aliquots will be analyzed by the ELISA method developed at NPL (see Appendix 2) on a single plate. Through comparison of the ELISA response from all 32 vials, Sample 1 demonstrated stability for all storage conditions for up to 28 days. For the Sample 1 aliquots stored at 22 °C and 5 °C for 48 days, there was a statistically significant decreased in the measured cTnI ELISA response relative to aliquots stored at -20 °C for 48 days and the control samples stored at -80 °C. As all three samples are similar in nearly every aspect, it is assumed that the stability observed for Sample 1 also reflect the stability of Sample 2 and Sample 3. 
Instructions for use
Methodology
Participants are requested to use their preferred 1+1 sandwich immunoassay methodology for the analysis of cTnI in each of the three samples. Because the antibodies used in an ELISA define the measurand, participants are also required to use the two supplied mouse monoclonal antibodies in their 1+1 sandwich immunoassay. An example of an ELISA method for cTnI measurement that was developed at NPL can be found in Appendix 2. Participants are required to use the supplied NIST SRM 2921 to prepare calibration solutions for their immunoassay measurement.
Reporting
Three results for the mass concentration of cTnI for each of the two vials of Samples 1 through 3 should be reported, as well as an overall combined result for both vials. 
Preparation of Solutions
Highly purified water should be used to prepare all solutions, comparable to bidistilled water (conductivity <0.055 µS/cm, TOC < 6 ppb, pH 6-7). Solutions should be filtered using a 0.2 µm (or similar pore size) filtration unit for prolonged storage. 
Measurement Procedure
The assay is typically run over two days consisting of antibody immobilisation (Day 1) and subsequent running of the assay (Day 2). The assay time can be shortened by running the antibody immobilisation step at ambient or elevated temperature for two hours.
Antibody immobilisation
a) Black high-binding polystyrene 96-well plates should be used for fluorescent assays to minimize reflection and scatter of light. The volumes given in this protocol are for the preparation of a single plate and should be adjusted accordingly for multiple plates. b) Prepare 10.5 mL of cTnI capture antibody (clone 560) by diluting to 2.5 mg/L in Solution 1. Note: the stock antibody concentration varies with batch but should be in the range of 3-10 g/L. c) Calculate the volume of capture antibody required based on the number of plates to prepare and the batch concentration of capture antibody stock. d) In a 15 mL plastic microfuge tube pipette the antibody stock, make up to 10.5 mL using Solution 1 and mix by inverting the capped tube. e) Pipette 100 µl of the diluted capture antibody into each well, tap the plate gently to ensure the bottom of each well is fully covered with liquid. f) Seal the plate using either a microplate seal, or cover with foil to avoid contamination and incubate overnight at 4 ºC g) Stability at 4 ºC: 2 days.
Blocking of the ELISA plate
Various blocking buffers have been tested and can be substituted for Solution 6. a) Wash the plate three times with 300 µL of Solution 2 per well. 
Preparation of calibration standards
The cRMP uses a 1-step ELISA format with sequential addition of the sample to the immobilised capture antibody, followed by the addition of the detection antibody conjugate. The cTnI SRM 2921 response curve is prepared from gravimetric dilution from a working stock solution. The preparation of the working stock solution '312 µg/L' from the SRM 2921 stock solution is performed as follows:
• Defrost the vial of SRM 2921 on ice.
Unused standard stock should be aliquoted into fresh microfuge tubes, and stored at ≤ -70 ºC within 30 minutes of defrosting the SRM vial (these aliquots can be used for repeats of the assay). Any unused SRM 2921 stock and subsequent dilutions should be discarded after this time period.
• Gravimetric dilution can be performed in 1.5 ml microfuge tubes. Each prepared dilution should be store on ice until use. Diluted standards should be discarded after analysis. Stability of dilutions at 4 ºC: ≤ 2 hours.
• Gravimetric weighing for preparation of the cTnI standards should be performed on an electronic balance with a minimum resolution of 0.1 mg.
• Weigh an approximately 10 µL aliquot of SRM 2921 into microfuge tube.
• Dilute with approximately 990 µL of Solution 3.
• Gently and thoroughly mix. Table A1 lists the steps for the preparation of the standard response plot, prepared from the working stock solution '312 µg/L' detailed above. When prepared each dilution should be stored on ice until addition to the plate. Participants can prepare the plate in any format (an example template layout is given at the end of this Appendix) Note: Table A1 gives instructions to prepare calibration solutions for a single plate, each repeated in triplicate. When more than one plate is run, the volumes may need to be adjusted accordingly.
Immunoassay Incubation
The samples are incubated in the plate in a 1-step reaction with the detection antibody. The preparation of the detection antibody is described section "Preparation of antibody clone 19C7-AP conjugate" below.
• Defrost the detection antibody on ice.
Described is the preparation of 5.5 mL of detection antibody conjugate, sufficient for the analysis of a single plate, if more plates are to be assayed increase the volume of antibody prepared as appropriate. Dilute the detection antibody in a microfuge tube to 0.5 mg/L in Solution 2, approximately 5.5 ml will need to be prepared for a single plate. Mix the solution by inverting the tube. Stability at ambient temperature: 2 hours.
• 
Measurement Procedure
The conditions for measuring the fluorescence of the 4-MUP substrate are given in Table A2 . • A physical plate standard in which solid phase fluorescent standard is present in all the wells (Matech, Westlake Village, CA).
• A liquid fluorescence standard that closely matches the excitation and emission peaks of 4-MUP, which can be pipetted into each well. Note that liquid transfer will generate uncertainty that will need to be assessed when using this approach.
Data Analysis
Plate reader instruments have different sensitivities therefore the quantitation range for the cTnI cRMP will vary between laboratories.
• Calculate the mean response from the blank (zero concentration standard) and subtract this from all the raw data values.
• Calculate the mean, standard deviation and % CV from all the data inputs. If sufficient replicates have been run outlier analysis techniques can be used to mark and exclude spurious data from single wells.
• From gravimetric data from the preparation of the samples for the standard response curve, calculate the corrected cTnI concentrations.
• Transform both the cTnI (ng/L) concentration and intensity values (arbitrary) into log values.
• Plot log concentration vs. log intensity for the cTnI standards and fit to a linear equation (y = ax + b). Determine quality and suitability of fit (see notes).
• Determine the concentration of the unknown samples using the equation derived above. Using anti-log convert to concentration estimates. Note: The quality of the fit can be assessed by looking at the R 2 value, ideally this should be greater than 0.99. However the R 2 values should not solely be relied upon. The quality of the fit can be assessed by back-calculating the concentration of the standards using the y 'intensity' data and the equation derived. The % bias between the two values should be less than 20. If bias values of greater than 20 % are observed at either end of the response curve this indicates the limits of the quantitation range.
Data Reporting
Estimates for the three undisclosed cTnI samples and the associated uncertainty should be provided. We would also be grateful if participants could provide the following:
• The raw, untransformed fluorescent data.
• Details of any equations, methods used to transform the data, or remove any outliers (with justifications).
• Equations used to fit the data and associated performance metrics, i.e. goodness of fit.
• Optional: A breakdown of the components of the uncertainty and associated equation.
Sources of error
If significant bias is observed upon back calculation of the standard response when fitting to a linear equation, significant errors in estimating unknowns using this data set will be obtained. The following should be considered if significant bias is observed:
• Re-measure the standards to confirm these bias limits and adjust the assay measurement range accordingly.
• Analyse more standard concentrations in the areas of greater bias, allowing more complex data fitting models to be tested (i.e. logistic), or the use of multiple fitting procedures to model the data.
Example of a plate template format
Shown below is an example of a plate template that can be copied for use in the 1 2 3 4 5 6 7 8 9 10 11 
Antibody conjugation
• Buffer exchange antibody solution (0.35 mg ~ 50 µL at ~ 6-8 g/L) into Solution 7 using centrifugation cartridges with a suitable cut-off (50 kDa).
• This step reduces the amount of contaminating sodium azide in the conjugation reaction.
• Exchange the buffer in the cartridge three times with Solution 7.
• Add the 19C7 sample, centrifuge and collect the liquid removed from the resin, estimate the volume of the buffer exchanged 19C7.
• Reconstitute the activated alkaline phosphatase in 0.5 mL of water, store unused reagent in 100 µL aliquots at −20 ºC after a snap freeze at −60 ⁰C.
• In a 1.5 ml microfuge tube add 50 µL of the 19C7 in Solution 7 and add 100 µL of activated alkaline phosphatase.
• Incubate this vial at 21 ⁰C ± 2 ⁰C for three hours, with the occasional mixing of the tube by vortex, or inversion. 
